ambien sleep aids

lianne soma

Viehbacher, Chief Executive Officer of sanofi-aventis.001) compared with placebo meeting the primary endpoint. Multaq should not be coadministered with strong CYP 3A inhibitors or medicinal products that prolong the QT interval. ambien sleep aids S. ambien sleep aids This trial showed that Multaq (dronedarone) 400 mg BID, in addition to standard therapy, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24% (p<0. cheap phentermine cheap drugs

"Sanofi-aventis is proud of its ability to bring innovative therapies to market and contribute to reducing the public health burden of atrial fibrillation.5 million people in the United States and 4. Atrial fibrillation is a potentially life-threatening condition, with significant burden on patients, health care providers and payers. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. ambien sleep aids The ATHENA and ANDROMEDA trials provided two sets of data supporting the assessment of the product's benefit risk ratio in two significantly different patient populations.5 million people in the United States and 4. ambien sleep aids 001) compared with placebo meeting the primary endpoint. Patients were predominantly NYHA II and III (New York Heart Association classification) and only 25% had a history of AF/AFL at randomization. effects of long term use tramadol

The FDA approval is based on five international, multi-center, randomized clinical trials involving nearly 6,300 patients. This unstable population corresponds to the population of the ANDROMEDA trial in which patients receiving dronedarone had a greater than 2-fold increase in mortality compared to placebo. The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance.5 million people in the European Union. ambien sleep aids " The landmark ATHENA trial evaluated the efficacy and safety of Multaq in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% were in NYHA class I-III with stable heart failure). Patients taking Multaq had higher rates of diarrhea, nausea, bradycardia, QT-interval prolongation and cutaneous rash than patients taking placebo. ambien sleep aids Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets.sanofi-aventis.